10-QPeriod: Q3 FY2023

INTUITIVE SURGICAL INC Quarterly Report for Q3 Ended Sep 30, 2023

Filed October 20, 2023For Securities:ISRG

Summary

Intuitive Surgical Inc. (ISRG) reported robust financial performance for the nine months ended September 30, 2023, with total revenue reaching $5.20 billion, a 14% increase year-over-year. This growth was driven by strong performance in instruments and accessories (up 22%) and service revenue (up 13%), indicating increased utilization of their da Vinci surgical systems. While system revenue saw a slight decrease of 2%, this was offset by a higher proportion of placements under operating leases, which generate recurring revenue over time. The company demonstrated solid profitability with an operating income of $1.32 billion for the nine-month period, up 9% year-over-year. Net income attributable to Intuitive Surgical, Inc. increased by 19% to $1.19 billion. The company maintained a strong liquidity position, with cash, cash equivalents, and investments totaling $7.52 billion as of September 30, 2023. ISRG also continued its commitment to shareholder returns, repurchasing $350 million of its common stock during the nine-month period, while maintaining a significant remaining authorization for future repurchases.

Financial Highlights

46 data points
Beta

Revenue

$1.74B

66.9% Gross Margin

Net Income

$415.70M

23.8% Net Margin

EPS (Diluted)

$1.16

Total Assets

$14.71B

Cash & Equivalents

$3.62B

Free Cash Flow

$548.40M

Financial Statements
Beta
Revenue$1.74B
Cost of Revenue$576.50M
Gross Profit$1.17B
R&D Expenses$249.40M
SG&A Expenses$452.00M
Operating Expenses$701.40M
Operating Income$465.80M
Net Income$415.70M
EPS (Basic)$1.18
EPS (Diluted)$1.16
Shares Outstanding (Basic)351.70M
Shares Outstanding (Diluted)358.20M

Key Highlights

  • 1Total revenue increased 14% to $5.20 billion for the first nine months of 2023.
  • 2Instruments and accessories revenue grew 22% to $3.13 billion, indicating strong procedure adoption.
  • 3Service revenue increased 13% to $863 million, driven by a growing installed base.
  • 4Net income attributable to Intuitive Surgical, Inc. rose 19% to $1.19 billion for the nine-month period.
  • 5Operating income reached $1.32 billion for the nine months, a 9% increase year-over-year.
  • 6The company ended the period with $7.52 billion in cash, cash equivalents, and investments, demonstrating a strong liquidity position.
  • 7The da Vinci system installed base grew 13% year-over-year to approximately 8,285 systems.

Frequently Asked Questions

Revenue growth was primarily driven by a 22% increase in instruments and accessories revenue and a 13% increase in service revenue. This indicates higher utilization of existing da Vinci surgical systems and continued strong procedure adoption. Systems revenue saw a slight decline, which was offset by a higher proportion of systems placed under operating leases, contributing to recurring revenue.

Profitability remained strong, with operating income increasing by 9% to $1.32 billion for the nine months ended September 30, 2023. Net income attributable to Intuitive Surgical, Inc. also saw significant growth, increasing by 19% to $1.19 billion, demonstrating the company's ability to manage costs effectively while expanding its top line.

Intuitive Surgical maintains a very strong liquidity position. As of September 30, 2023, the company held $7.52 billion in cash, cash equivalents, and investments. This substantial cash balance, combined with positive cash flow from operations, provides significant financial flexibility for ongoing investments in R&D, capital expenditures, and potential future acquisitions or shareholder returns.

The company acknowledges ongoing macroeconomic challenges such as inflation, higher interest rates, and supply chain constraints. They are actively seeking to mitigate these impacts through various activities, including enhanced supplier communication, adjusted purchase order coverage, and inventory management. Despite these challenges, the company has so far not experienced material adverse impacts on its results of operations or ability to deliver products and services.